Assessing the potential of NS2B/NS3 protease inhibitors biomarker in curbing dengue virus infections: In silico vs. In vitro approach
An increase in the occurrence of viral infectious diseases is a global concern for human health. According to a WHO report, dengue virus (DENV) is one of the most common viral diseases affecting approximately 400 million people annually, with worsening symptoms in nearly 1% of cases. Both academic a...
Autors principals: | Harun Norshidah, Chiuan Herng Leow, Kamarulzaman Ezatul Ezleen, Habibah A. Wahab, Ramachandran Vignesh, Azhar Rasul, Ngit Shin Lai |
---|---|
Format: | Article |
Idioma: | English |
Publicat: |
Frontiers Media S.A.
2023-02-01
|
Col·lecció: | Frontiers in Cellular and Infection Microbiology |
Matèries: | |
Accés en línia: | https://www.frontiersin.org/articles/10.3389/fcimb.2023.1061937/full |
Ítems similars
-
Updates on Dengue Vaccine and Antiviral: Where Are We Heading?
per: Harun Norshidah, et al.
Publicat: (2021-11-01) -
Synthesis and biological activity of imidazole phenazine derivatives as potential inhibitors for NS2B-NS3 dengue protease
per: Nur Sarah Dyana Khalili, et al.
Publicat: (2024-01-01) -
Design, Synthesis, and in-vitro Protease Inhibition Assay of Linear Pentapeptides as Potential Dengue Virus NS2B/NS3 Protease Inhibitors
per: NADEEM ABDALRAZAQ, et al.
Publicat: (2022-04-01) -
The flavivirus NS2B–NS3 protease–helicase as a target for antiviral drug development
per: Luo, Dahai, et al.
Publicat: (2016) -
Lambda-free light chain: A serum marker of dengue disease via NS3 protease-mediated antibody cleavage
per: Sheng-Hsuan Wang, et al.
Publicat: (2023-12-01)